Albumin-encapsulated HSP90-PROTAC BP3 nanoparticles not only retain protein degradation ability but also enhance the antitumour activity of BP3 in vivo.

MLA

Jiang, Qingna, et al. “Albumin-Encapsulated HSP90-PROTAC BP3 Nanoparticles Not Only Retain Protein Degradation Ability but Also Enhance the Antitumour Activity of BP3 in Vivo.” Journal of Drug Targeting, vol. 31, no. 4, Apr. 2023, pp. 411–20. EBSCOhost, https://doi.org/10.1080/1061186X.2023.2185247.

APA

Jiang, Q., Hu, Y., Liu, Q., Tang, Y., Wu, X., Liu, J., Tu, G., Li, G., Lin, X., Qu, M., Cai, Y., Huang, X., Xu, J., Deng, Y., Chen, Z., & Wu, L. (2023). Albumin-encapsulated HSP90-PROTAC BP3 nanoparticles not only retain protein degradation ability but also enhance the antitumour activity of BP3 in vivo. Journal of Drug Targeting, 31(4), 411–420. https://doi.org/10.1080/1061186X.2023.2185247

Chicago

Jiang, Qingna, Yan Hu, Quanyu Liu, Yuanling Tang, Xinhua Wu, Jingwen Liu, Guihui Tu, et al. 2023. “Albumin-Encapsulated HSP90-PROTAC BP3 Nanoparticles Not Only Retain Protein Degradation Ability but Also Enhance the Antitumour Activity of BP3 in Vivo.” Journal of Drug Targeting 31 (4): 411–20. doi:10.1080/1061186X.2023.2185247.